Genomics of the Psychedelic Frontier: Inside Tryptomics with Chris Pauli

From Patient Zero to Founder with Rogers Masson

A Veteran's Mission to Redesign Immersive Sound Therapy What happens when the music meant to support healing becomes its own source of disruption? Rogers Masson knows firsthand. A U.S. Army veteran and Grammy-voting music producer who spent over three decades living with PTSD, Masson entered the MAPS/FDA expanded access MDMA-assisted therapy trials at the Pearl Institute in Asheville, North Carolina — and emerged as Patient 001 with a mission. The standard therapeutic playlists he encountered during treatment were, by his account and his therapists' own admission, a known problem. Rather than accept it, Masson paused a 25-year career and built PsySonics: immersive, psychoacoustic sound engineered from the ground up for MDMA, ketamine, and psilocybin sessions. On this episode of Inside the Revival, host Jim Tate explores the science, design, and personal conviction behind a tool now used in clinical trials and trusted therapeutic practices across the psychedelic ecosystem.

Genomics of the Psychedelic Frontier: Inside Tryptomics with Chris Pauli

On this episode, host Jim Tate sits down with Chris Pauli, Co-Founder and Molecular Biologist at Tryptomics, a Colorado-based biotech laboratory pioneering testing and research services for psychoactive plants and fungi. From his early work sequencing the cannabis genome to building one of the first dedicated psychedelic testing labs, Pauli brings a rigorous scientific lens to a field that urgently needs one. The conversation covers the extraordinary variability in psilocybin potency across mushroom strains and flush cycles; the case for full-spectrum "ensemble" medicine over single-compound isolates; the emerging science of pharmacogenomics and what it could mean for personalized psychedelic therapy; Colorado's landmark Natural Medicine Health Act (Proposition 122) and the regulatory challenges ahead for ibogaine and DMT; and the troubling proliferation of synthetic tryptamines in the unregulated market.

Ontological Shock & the Healing Threshold with Peter Addy, PhD.

S1E18: Ontological Shock and the Healing Threshold: A Psychedelic Clinician’s Field Guide with Peter Addy, PhD. Join host Jim Tate sits and his guest psychedelic researcher and psychotherapist Peter Addy, PhD for an honest, nuanced, and scientifically grounded survey of the current psychedelic landscape. From the mechanics of harm reduction and integration therapy to the politics of federal scheduling, the conversation moves fluidly between clinical science, cultural history, and personal experience. He addresses the promise and peril of the commercial psychedelic industry, reflects on Oregon’s pioneering psilocybin services framework, examines the FDA’s rejection of MDMA-assisted psychotherapy, and shares first-hand accounts from his clinical work with chronic pain patients. He also draws on deep field experience studying Salvia divinorum, including travel to Oaxaca, Mexico and years of postdoctoral research at Yale. Equal parts scholar, clinician, and thoughtful advocate, Dr. Addy offers a rare combination of scientific rigor and compassionate practice.

Healing From the Inside Out with Bénédicte Mannix

S1E17: Healing From the Inside Out: Bénédicte Mannix on Psilocybin, Mental Homeostasis, and the Art of the Private Retreat Join host Jim Tate and his guest Bénédicte (Ben) Mannix , holistic psilocybin therapist, sophrotherapist, and founder of Sophrodelic in Kingston, Jamaica for a candid and illuminating conversation about what truly personalized psychedelic-assisted therapy looks and feels like in practice.

Clearing the Plaque with Adam Butler

S1E16: Clearing the Plaque: How DMT Saved One Man's Life and What Science Is Beginning to Confirm Join host Jim Tate and his guest DMT Field Guide author Adam Butler, psychedelic philosopher, prolific author, and passionate DMT advocate , for a candid, deeply personal conversation at the intersection of mental health, neuroplasticity, and the emerging science of psychedelic medicine. Butler, author of Butler's DMT Field Guide: A Brief History, Step-by-Step Recipes, and Personal Experiences From a DMT Saturated Consciousness, shares how N,N-dimethyltryptamine pulled him back from the edge of suicide and addiction, and why he believes, with growing scientific backing that this endogenous molecule may hold keys to treating everything from depression and PTSD to stroke and dementia. From harm reduction and ontological risk to extended-state DMT research, microdosing philosophy, and the urgent need for philanthropic investment in psychedelic science, this episode maps the terrain for anyone curious about the revival happening at the frontier of mind, medicine, and healing.